Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Canepa

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
European Journal of Preventive Cardiology|September 9, 2021
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE StudyMarco Merlo, Aldostefano Porcari, Linda Pagura, et al.
European Journal of Heart Failure|November 29, 2025
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidisAldostefano Porcari, Paolo Milani, Simone Longhi, et al.
European Journal of Heart Failure|March 12, 2023
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network studyGiacomo Tini, Paolo Milani, Mattia Zampieri, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|February 17, 2026
Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-studyLaura De Michieli, Giacomo Tini, Alessia Argirò, et al.
JACC. Heart Failure|July 3, 2025
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With TafamidisGiulio Sinigiani, Giuseppe Damiano Sanna, Alberto Aimo, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 26, 2025
Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosisAlberto Aimo, Paolo Milani, Giacomo Tini, et al.
European Journal of Heart Failure|April 13, 2022
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide surveyMarco Merlo, Linda Pagura, Aldostefano Porcari, et al.
ESC Heart Failure|September 20, 2024
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND studyGiacomo Tini, Beatrice Musumeci, Paolo Milani, et al.
Circulation. Genomic and Precision Medicine|July 8, 2026
Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter RegistryMaria Perotto, Cinzia Radesich, Alessia Paldino, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|June 27, 2025
Myosin-ATPase inhibitor in real-world patients with obstructive HCM: a report by the Cardiomyopathies and Pericardial Diseases WG of the Italian Society of CardiologyCesare de Gregorio, Paolo Bellocchi, Anna Rosa Napoli, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
European Journal of Preventive Cardiology|September 9, 2021
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE StudyMarco Merlo, Aldostefano Porcari, Linda Pagura, et al.
European Journal of Heart Failure|November 29, 2025
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidisAldostefano Porcari, Paolo Milani, Simone Longhi, et al.
European Journal of Heart Failure|March 12, 2023
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network studyGiacomo Tini, Paolo Milani, Mattia Zampieri, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|February 17, 2026
Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-studyLaura De Michieli, Giacomo Tini, Alessia Argirò, et al.
JACC. Heart Failure|July 3, 2025
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With TafamidisGiulio Sinigiani, Giuseppe Damiano Sanna, Alberto Aimo, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 26, 2025
Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosisAlberto Aimo, Paolo Milani, Giacomo Tini, et al.
European Journal of Heart Failure|April 13, 2022
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide surveyMarco Merlo, Linda Pagura, Aldostefano Porcari, et al.
ESC Heart Failure|September 20, 2024
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND studyGiacomo Tini, Beatrice Musumeci, Paolo Milani, et al.
Circulation. Genomic and Precision Medicine|July 8, 2026
Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter RegistryMaria Perotto, Cinzia Radesich, Alessia Paldino, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|June 27, 2025
Myosin-ATPase inhibitor in real-world patients with obstructive HCM: a report by the Cardiomyopathies and Pericardial Diseases WG of the Italian Society of CardiologyCesare de Gregorio, Paolo Bellocchi, Anna Rosa Napoli, et al.
Pageof 17